Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) were up 2.8% on Friday . The stock traded as high as $7.09 and last traded at $7.03, with a volume of 80,456 shares trading hands. The stock had previously closed at $6.84.

Several analysts have recently weighed in on NEOS shares. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Wells Fargo & Co. reissued a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Royal Bank Of Canada dropped their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, May 17th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $15.00 price target on shares of Neos Therapeutics in a research note on Tuesday, July 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.75.

The company’s market capitalization is $112.17 million. The firm has a 50-day moving average price of $8.57 and a 200-day moving average price of $9.50.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by $0.49. The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $1.48 million. Equities analysts expect that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current fiscal year.

In related news, insider Juergen Martens acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average price of $9.90 per share, with a total value of $99,000.00. Following the completion of the acquisition, the insider now owns 10,000 shares in the company, valued at $99,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP increased its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.